Cargando…
Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Have No Significant Relationship With Postoperative Arthrofibrosis After Shoulder Arthroscopy
PURPOSE: To determine the effect of perioperative angiotensin II receptor blocker (ARB) or angiotensin-converting enzyme inhibitors (ACEi) on postoperative arthrofibrosis, as defined by requiring manipulation under anesthesia (MUA) or new diagnosis of adhesive capsulitis (AC) following arthroscopic...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461208/ https://www.ncbi.nlm.nih.gov/pubmed/37645401 http://dx.doi.org/10.1016/j.asmr.2023.05.005 |
_version_ | 1785097807354396672 |
---|---|
author | Bi, Andrew S. Li, Zachary I. Triana, Jairo Fisher, Nina D. Morgan, Allison M. Garra, Sharif Gonzalez-Lomas, Guillem Campbell, Kirk A. Jazrawi, Laith M. |
author_facet | Bi, Andrew S. Li, Zachary I. Triana, Jairo Fisher, Nina D. Morgan, Allison M. Garra, Sharif Gonzalez-Lomas, Guillem Campbell, Kirk A. Jazrawi, Laith M. |
author_sort | Bi, Andrew S. |
collection | PubMed |
description | PURPOSE: To determine the effect of perioperative angiotensin II receptor blocker (ARB) or angiotensin-converting enzyme inhibitors (ACEi) on postoperative arthrofibrosis, as defined by requiring manipulation under anesthesia (MUA) or new diagnosis of adhesive capsulitis (AC) following arthroscopic shoulder procedures. METHODS: Patients were retrospectively identified using Current Procedural Terminology surgical billing codes to identify patients who underwent any shoulder arthroscopic procedure at a single urban academic institution from 2012 to 2020 with a minimum 2-year follow-up. Patients were excluded if <30 years old at time of surgery, as these patients rarely use ARB and ACEi medications, or if they had pre-existing AC. Demographics, active medication prescriptions at the time of surgery, and medical comorbidities were recorded. Multivariable logistic regression was performed to determine the effect of ARB/ACEi on subsequent MUA or AC by 90 days, 1 year, and 2 years. RESULTS: In total, 5,559 patients were included in the final analysis. A majority of the cohort (53.4%) underwent arthroscopic surgery between the ages of 50 to 69 years. Most patients were male (61.8%) and without obesity (67.3%). In total, 18.9% and 15.0% were taking an ARB or ACEi medication perioperatively, respectively. Within 2 years’ postoperatively, 51 patients (0.9%) underwent subsequent ipsilateral MUA, and 174 patients (3.1%) developed AC. Patients taking ARBs had a 17.5% rate of postoperative arthrofibrosis within 2-years compared with 19.1% in those not on ARBs, although this difference was not significant (P = .58). Likewise, no significant difference was found between those taking ACEi versus not (15.0% vs 15.0%, P = .99). Individual generic ARB/ACEi subgroup analysis did not demonstrate any significant associations with rate of postoperative arthrofibrosis (P > .05). CONCLUSIONS: ARBs or ACEi did not significantly affect the rate of postoperative arthrofibrosis following shoulder arthroscopy, however female sex, diabetes mellitus, and Black/African American race were associated with an increased rate of necessitating MUA or developing AC within 2 years postoperatively. LEVEL OF EVIDENCE: Level III, retrospective cohort study. |
format | Online Article Text |
id | pubmed-10461208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-104612082023-08-29 Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Have No Significant Relationship With Postoperative Arthrofibrosis After Shoulder Arthroscopy Bi, Andrew S. Li, Zachary I. Triana, Jairo Fisher, Nina D. Morgan, Allison M. Garra, Sharif Gonzalez-Lomas, Guillem Campbell, Kirk A. Jazrawi, Laith M. Arthrosc Sports Med Rehabil Original Article PURPOSE: To determine the effect of perioperative angiotensin II receptor blocker (ARB) or angiotensin-converting enzyme inhibitors (ACEi) on postoperative arthrofibrosis, as defined by requiring manipulation under anesthesia (MUA) or new diagnosis of adhesive capsulitis (AC) following arthroscopic shoulder procedures. METHODS: Patients were retrospectively identified using Current Procedural Terminology surgical billing codes to identify patients who underwent any shoulder arthroscopic procedure at a single urban academic institution from 2012 to 2020 with a minimum 2-year follow-up. Patients were excluded if <30 years old at time of surgery, as these patients rarely use ARB and ACEi medications, or if they had pre-existing AC. Demographics, active medication prescriptions at the time of surgery, and medical comorbidities were recorded. Multivariable logistic regression was performed to determine the effect of ARB/ACEi on subsequent MUA or AC by 90 days, 1 year, and 2 years. RESULTS: In total, 5,559 patients were included in the final analysis. A majority of the cohort (53.4%) underwent arthroscopic surgery between the ages of 50 to 69 years. Most patients were male (61.8%) and without obesity (67.3%). In total, 18.9% and 15.0% were taking an ARB or ACEi medication perioperatively, respectively. Within 2 years’ postoperatively, 51 patients (0.9%) underwent subsequent ipsilateral MUA, and 174 patients (3.1%) developed AC. Patients taking ARBs had a 17.5% rate of postoperative arthrofibrosis within 2-years compared with 19.1% in those not on ARBs, although this difference was not significant (P = .58). Likewise, no significant difference was found between those taking ACEi versus not (15.0% vs 15.0%, P = .99). Individual generic ARB/ACEi subgroup analysis did not demonstrate any significant associations with rate of postoperative arthrofibrosis (P > .05). CONCLUSIONS: ARBs or ACEi did not significantly affect the rate of postoperative arthrofibrosis following shoulder arthroscopy, however female sex, diabetes mellitus, and Black/African American race were associated with an increased rate of necessitating MUA or developing AC within 2 years postoperatively. LEVEL OF EVIDENCE: Level III, retrospective cohort study. Elsevier 2023-07-01 /pmc/articles/PMC10461208/ /pubmed/37645401 http://dx.doi.org/10.1016/j.asmr.2023.05.005 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Bi, Andrew S. Li, Zachary I. Triana, Jairo Fisher, Nina D. Morgan, Allison M. Garra, Sharif Gonzalez-Lomas, Guillem Campbell, Kirk A. Jazrawi, Laith M. Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Have No Significant Relationship With Postoperative Arthrofibrosis After Shoulder Arthroscopy |
title | Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Have No Significant Relationship With Postoperative Arthrofibrosis After Shoulder Arthroscopy |
title_full | Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Have No Significant Relationship With Postoperative Arthrofibrosis After Shoulder Arthroscopy |
title_fullStr | Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Have No Significant Relationship With Postoperative Arthrofibrosis After Shoulder Arthroscopy |
title_full_unstemmed | Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Have No Significant Relationship With Postoperative Arthrofibrosis After Shoulder Arthroscopy |
title_short | Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Have No Significant Relationship With Postoperative Arthrofibrosis After Shoulder Arthroscopy |
title_sort | angiotensin receptor blockers and angiotensin-converting enzyme inhibitors have no significant relationship with postoperative arthrofibrosis after shoulder arthroscopy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461208/ https://www.ncbi.nlm.nih.gov/pubmed/37645401 http://dx.doi.org/10.1016/j.asmr.2023.05.005 |
work_keys_str_mv | AT biandrews angiotensinreceptorblockersandangiotensinconvertingenzymeinhibitorshavenosignificantrelationshipwithpostoperativearthrofibrosisaftershoulderarthroscopy AT lizacharyi angiotensinreceptorblockersandangiotensinconvertingenzymeinhibitorshavenosignificantrelationshipwithpostoperativearthrofibrosisaftershoulderarthroscopy AT trianajairo angiotensinreceptorblockersandangiotensinconvertingenzymeinhibitorshavenosignificantrelationshipwithpostoperativearthrofibrosisaftershoulderarthroscopy AT fisherninad angiotensinreceptorblockersandangiotensinconvertingenzymeinhibitorshavenosignificantrelationshipwithpostoperativearthrofibrosisaftershoulderarthroscopy AT morganallisonm angiotensinreceptorblockersandangiotensinconvertingenzymeinhibitorshavenosignificantrelationshipwithpostoperativearthrofibrosisaftershoulderarthroscopy AT garrasharif angiotensinreceptorblockersandangiotensinconvertingenzymeinhibitorshavenosignificantrelationshipwithpostoperativearthrofibrosisaftershoulderarthroscopy AT gonzalezlomasguillem angiotensinreceptorblockersandangiotensinconvertingenzymeinhibitorshavenosignificantrelationshipwithpostoperativearthrofibrosisaftershoulderarthroscopy AT campbellkirka angiotensinreceptorblockersandangiotensinconvertingenzymeinhibitorshavenosignificantrelationshipwithpostoperativearthrofibrosisaftershoulderarthroscopy AT jazrawilaithm angiotensinreceptorblockersandangiotensinconvertingenzymeinhibitorshavenosignificantrelationshipwithpostoperativearthrofibrosisaftershoulderarthroscopy |